- All sections
- A - Human necessities
- A61K - Preparations for medical, dental or toiletry purposes
- A61K 31/5375 - 1,4-Oxazines, e.g. morpholine
Patent holdings for IPC class A61K 31/5375
Total number of patents in this class: 1616
10-year publication summary
|
101
|
102
|
104
|
103
|
98
|
90
|
81
|
96
|
98
|
3
|
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| Supernus Pharmaceuticals, Inc. | 135 |
25 |
| Apnimed, Inc. (Delaware) | 53 |
22 |
| Axsome Therapeutics, Inc. | 284 |
20 |
| Bristol-myers Squibb Company | 4793 |
19 |
| Novartis AG | 10511 |
15 |
| Allergan, Inc. | 2310 |
15 |
| Aeromics, Inc. | 29 |
13 |
| The Regents of the University of California | 20315 |
11 |
| Arbor Pharmaceuticals, LLC | 67 |
11 |
| Epizyme, Inc. | 371 |
11 |
| Gilead Sciences, Inc. | 2112 |
11 |
| Boehringer Ingelheim International GmbH | 4596 |
10 |
| Centre National de La Recherche Scientifique | 10726 |
10 |
| Mitsubishi Tanabe Pharma Corporation | 563 |
10 |
| The United States of America, as represented by the Secretary, Department of Health and Human Services | 2918 |
10 |
| Advanced Biodesign | 21 |
9 |
| Astellas Pharma Inc. | 1048 |
9 |
| The Cleveland Clinic Foundation | 1577 |
9 |
| Global Blood Therapeutics, Inc. | 182 |
9 |
| XenoPort, Inc. | 81 |
9 |
| Other owners | 1358 |